Anbio Biotechnology (NNNN) Competitors

$26.94 +1.87 (+7.46%)

Closing price 04:00 PM Eastern

Extended Trading

$26.25 -0.69 (-2.56%)

As of 05:34 PM Eastern

NNNN vs. RGC, BBIO, AXSM, ARWR, and ELAN

Should you buy Anbio Biotechnology stock or one of its competitors? MarketBeat compares Anbio Biotechnology with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Anbio Biotechnology include Regencell Bioscience (RGC), BridgeBio Pharma (BBIO), Axsome Therapeutics (AXSM), Arrowhead Pharmaceuticals (ARWR), and Elanco Animal Health (ELAN). These companies are all part of the "pharmaceutical products" industry.

How does Anbio Biotechnology compare to Regencell Bioscience?

Regencell Bioscience (NASDAQ:RGC) and Anbio Biotechnology (NASDAQ:NNNN) are both manufacturing companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, risk, earnings, institutional ownership, media sentiment, dividends, valuation and profitability.

Company	Net Margins	Return on Equity	Return on Assets
Regencell Bioscience	N/A	N/A	N/A
Anbio Biotechnology	N/A	N/A	N/A

Regencell Bioscience has a beta of 1.88, suggesting that its share price is 88% more volatile than the broader market. Comparatively, Anbio Biotechnology has a beta of 4.71, suggesting that its share price is 371% more volatile than the broader market.

Anbio Biotechnology has higher revenue and earnings than Regencell Bioscience.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Regencell Bioscience	N/A	N/A	-$3.58M	N/A	N/A
Anbio Biotechnology	$8.65M	448.14	$6.40M	N/A	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Regencell Bioscience	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Anbio Biotechnology	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

0.1% of Regencell Bioscience shares are held by institutional investors. 2.0% of Regencell Bioscience shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, Regencell Bioscience had 21 more articles in the media than Anbio Biotechnology. MarketBeat recorded 22 mentions for Regencell Bioscience and 1 mentions for Anbio Biotechnology. Anbio Biotechnology's average media sentiment score of 1.49 beat Regencell Bioscience's score of 0.04 indicating that Anbio Biotechnology is being referred to more favorably in the news media.

Company	Overall Sentiment
Regencell Bioscience	Neutral
Anbio Biotechnology	Positive

Summary

Anbio Biotechnology beats Regencell Bioscience on 5 of the 8 factors compared between the two stocks.

How does Anbio Biotechnology compare to BridgeBio Pharma?

BridgeBio Pharma (NASDAQ:BBIO) and Anbio Biotechnology (NASDAQ:NNNN) are both pharmaceutical products companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, risk, earnings, institutional ownership, media sentiment, dividends, valuation and profitability.

Anbio Biotechnology has a net margin of 0.00% compared to BridgeBio Pharma's net margin of -124.42%.

Company	Net Margins	Return on Equity	Return on Assets
BridgeBio Pharma	-124.42%	N/A	-65.81%
Anbio Biotechnology	N/A	N/A	N/A

BridgeBio Pharma has a beta of 1.02, suggesting that its share price is 2% more volatile than the broader market. Comparatively, Anbio Biotechnology has a beta of 4.71, suggesting that its share price is 371% more volatile than the broader market.

Anbio Biotechnology has lower revenue, but higher earnings than BridgeBio Pharma.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BridgeBio Pharma	$502.08M	25.80	-$724.93M	-$3.74	N/A
Anbio Biotechnology	$8.65M	448.14	$6.40M	N/A	N/A

BridgeBio Pharma presently has a consensus target price of $88.19, suggesting a potential upside of 33.36%. Given BridgeBio Pharma's stronger consensus rating and higher probable upside, analysts plainly believe BridgeBio Pharma is more favorable than Anbio Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BridgeBio Pharma	1 Sell rating(s)	0 Hold rating(s)	24 Buy rating(s)	0 Strong Buy rating(s)	2.92
Anbio Biotechnology	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

99.9% of BridgeBio Pharma shares are held by institutional investors. 14.2% of BridgeBio Pharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, BridgeBio Pharma had 32 more articles in the media than Anbio Biotechnology. MarketBeat recorded 33 mentions for BridgeBio Pharma and 1 mentions for Anbio Biotechnology. Anbio Biotechnology's average media sentiment score of 1.49 beat BridgeBio Pharma's score of 0.64 indicating that Anbio Biotechnology is being referred to more favorably in the news media.

Company	Overall Sentiment
BridgeBio Pharma	Positive
Anbio Biotechnology	Positive

Summary

BridgeBio Pharma beats Anbio Biotechnology on 7 of the 13 factors compared between the two stocks.

How does Anbio Biotechnology compare to Axsome Therapeutics?

Axsome Therapeutics (NASDAQ:AXSM) and Anbio Biotechnology (NASDAQ:NNNN) are both pharmaceutical products companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, risk, earnings, institutional ownership, media sentiment, dividends, valuation and profitability.

Axsome Therapeutics has a beta of 0.59, suggesting that its share price is 41% less volatile than the broader market. Comparatively, Anbio Biotechnology has a beta of 4.71, suggesting that its share price is 371% more volatile than the broader market.

Axsome Therapeutics presently has a consensus target price of $251.26, suggesting a potential upside of 10.34%. Given Axsome Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Axsome Therapeutics is more favorable than Anbio Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Axsome Therapeutics	1 Sell rating(s)	1 Hold rating(s)	18 Buy rating(s)	1 Strong Buy rating(s)	2.90
Anbio Biotechnology	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Axsome Therapeutics had 4 more articles in the media than Anbio Biotechnology. MarketBeat recorded 5 mentions for Axsome Therapeutics and 1 mentions for Anbio Biotechnology. Anbio Biotechnology's average media sentiment score of 1.49 beat Axsome Therapeutics' score of 0.72 indicating that Anbio Biotechnology is being referred to more favorably in the news media.

Company	Overall Sentiment
Axsome Therapeutics	Positive
Anbio Biotechnology	Positive

Anbio Biotechnology has lower revenue, but higher earnings than Axsome Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Axsome Therapeutics	$638.50M	18.35	-$183.17M	-$3.73	N/A
Anbio Biotechnology	$8.65M	448.14	$6.40M	N/A	N/A

81.5% of Axsome Therapeutics shares are held by institutional investors. 20.6% of Axsome Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Anbio Biotechnology has a net margin of 0.00% compared to Axsome Therapeutics' net margin of -26.59%. Anbio Biotechnology's return on equity of 0.00% beat Axsome Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Axsome Therapeutics	-26.59%	-267.16%	-28.53%
Anbio Biotechnology	N/A	N/A	N/A

Summary

Axsome Therapeutics beats Anbio Biotechnology on 8 of the 15 factors compared between the two stocks.

How does Anbio Biotechnology compare to Arrowhead Pharmaceuticals?

Anbio Biotechnology (NASDAQ:NNNN) and Arrowhead Pharmaceuticals (NASDAQ:ARWR) are both pharmaceutical products companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, risk, profitability, dividends, valuation, institutional ownership and earnings.

Anbio Biotechnology has a beta of 4.71, indicating that its stock price is 371% more volatile than the broader market. Comparatively, Arrowhead Pharmaceuticals has a beta of 1.28, indicating that its stock price is 28% more volatile than the broader market.

Arrowhead Pharmaceuticals has a consensus target price of $87.80, suggesting a potential upside of 14.52%. Given Arrowhead Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Arrowhead Pharmaceuticals is more favorable than Anbio Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Anbio Biotechnology	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Arrowhead Pharmaceuticals	0 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.83

In the previous week, Arrowhead Pharmaceuticals had 27 more articles in the media than Anbio Biotechnology. MarketBeat recorded 28 mentions for Arrowhead Pharmaceuticals and 1 mentions for Anbio Biotechnology. Anbio Biotechnology's average media sentiment score of 1.49 beat Arrowhead Pharmaceuticals' score of 0.48 indicating that Anbio Biotechnology is being referred to more favorably in the media.

Company	Overall Sentiment
Anbio Biotechnology	Positive
Arrowhead Pharmaceuticals	Neutral

Anbio Biotechnology has higher earnings, but lower revenue than Arrowhead Pharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Anbio Biotechnology	$8.65M	448.14	$6.40M	N/A	N/A
Arrowhead Pharmaceuticals	$829.45M	13.02	-$1.63M	-$2.15	N/A

62.6% of Arrowhead Pharmaceuticals shares are owned by institutional investors. 3.6% of Arrowhead Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Anbio Biotechnology has a net margin of 0.00% compared to Arrowhead Pharmaceuticals' net margin of -48.38%. Anbio Biotechnology's return on equity of 0.00% beat Arrowhead Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Anbio Biotechnology	N/A	N/A	N/A
Arrowhead Pharmaceuticals	-48.38%	-55.09%	-18.13%

Summary

Arrowhead Pharmaceuticals beats Anbio Biotechnology on 8 of the 15 factors compared between the two stocks.

How does Anbio Biotechnology compare to Elanco Animal Health?

Anbio Biotechnology (NASDAQ:NNNN) and Elanco Animal Health (NYSE:ELAN) are both pharmaceutical products companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, risk, profitability, dividends, valuation, institutional ownership and earnings.

Anbio Biotechnology has a beta of 4.71, indicating that its stock price is 371% more volatile than the broader market. Comparatively, Elanco Animal Health has a beta of 1.69, indicating that its stock price is 69% more volatile than the broader market.

Elanco Animal Health has a consensus target price of $28.20, suggesting a potential upside of 42.04%. Given Elanco Animal Health's stronger consensus rating and higher possible upside, analysts plainly believe Elanco Animal Health is more favorable than Anbio Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Anbio Biotechnology	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Elanco Animal Health	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.77

In the previous week, Elanco Animal Health had 4 more articles in the media than Anbio Biotechnology. MarketBeat recorded 5 mentions for Elanco Animal Health and 1 mentions for Anbio Biotechnology. Anbio Biotechnology's average media sentiment score of 1.49 beat Elanco Animal Health's score of 0.14 indicating that Anbio Biotechnology is being referred to more favorably in the media.

Company	Overall Sentiment
Anbio Biotechnology	Positive
Elanco Animal Health	Neutral

Anbio Biotechnology has higher earnings, but lower revenue than Elanco Animal Health.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Anbio Biotechnology	$8.65M	448.14	$6.40M	N/A	N/A
Elanco Animal Health	$4.72B	2.10	-$232M	-$0.50	N/A

97.5% of Elanco Animal Health shares are owned by institutional investors. 1.1% of Elanco Animal Health shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Anbio Biotechnology has a net margin of 0.00% compared to Elanco Animal Health's net margin of -4.95%. Elanco Animal Health's return on equity of 7.42% beat Anbio Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Anbio Biotechnology	N/A	N/A	N/A
Elanco Animal Health	-4.95%	7.42%	3.66%

Summary

Elanco Animal Health beats Anbio Biotechnology on 10 of the 15 factors compared between the two stocks.

Get Anbio Biotechnology News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NNNN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NNNN vs. The Competition

Export

Metric	Anbio Biotechnology	In Vitro, In Vivo Diagnostic Substances Industry	Manufacturing Sector	NASDAQ Exchange
Market Cap	$3.61B	$962.42M	$4.22B	$12.47B
Dividend Yield	N/A	N/A	5.92%	5.28%
P/E Ratio	N/A	N/A	22.86	25.24
Price / Sales	448.14	249.62	162.73	77.07
Price / Cash	563.30	563.30	50.14	56.01
Price / Book	128.29	64.56	38.26	6.91
Net Income	$6.40M	-$18.48M	$113.55M	$333.88M
7 Day Performance	4.26%	8.00%	2.60%	0.01%
1 Month Performance	-2.04%	24.30%	4.57%	1.75%
1 Year Performance	N/A	-62.91%	16.53%	32.67%

Anbio Biotechnology Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NNNN Anbio Biotechnology	1.319 of 5 stars	$26.94 +7.5%	N/A	N/A	$3.61B	$8.65M	N/A	27	Analyst Upgrade
RGC Regencell Bioscience	0.3507 of 5 stars	$27.87 +5.7%	N/A	N/A	$13.78B	N/A	N/A	10	Earnings Report
BBIO BridgeBio Pharma	3.4481 of 5 stars	$66.02 +0.1%	$88.19 +33.6%	+107.0%	$12.91B	$502.08M	N/A	400	Analyst Revision
AXSM Axsome Therapeutics	2.7349 of 5 stars	$227.49 +1.5%	$251.26 +10.5%	+124.0%	$11.69B	$638.50M	N/A	380
ARWR Arrowhead Pharmaceuticals	2.1632 of 5 stars	$79.86 +1.0%	$92.44 +15.8%	+434.5%	$11.27B	$622.01M	N/A	400	Trending News Analyst Forecast Insider Trade Analyst Revision

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:NNNN) was last updated on 5/15/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Anbio Biotechnology (NNNN) Competitors

NNNN vs. RGC, BBIO, AXSM, ARWR, and ELAN

How does Anbio Biotechnology compare to Regencell Bioscience?

Summary

How does Anbio Biotechnology compare to BridgeBio Pharma?

Summary

How does Anbio Biotechnology compare to Axsome Therapeutics?

Summary

How does Anbio Biotechnology compare to Arrowhead Pharmaceuticals?

Summary

How does Anbio Biotechnology compare to Elanco Animal Health?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NNNN vs. The Competition

Anbio Biotechnology Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Anbio Biotechnology (NNNN) Competitors

NNNN vs. RGC, BBIO, AXSM, ARWR, and ELAN

How does Anbio Biotechnology compare to Regencell Bioscience?

Is RGC or NNNN more profitable?

Which has more risk & volatility, RGC or NNNN?

Which has stronger earnings and valuation, RGC or NNNN?

Do analysts recommend RGC or NNNN?

Do insiders and institutionals hold more shares of RGC or NNNN?

Does the media prefer RGC or NNNN?

Summary

How does Anbio Biotechnology compare to BridgeBio Pharma?

Is BBIO or NNNN more profitable?

Which has more risk & volatility, BBIO or NNNN?

Which has stronger earnings and valuation, BBIO or NNNN?

Do analysts recommend BBIO or NNNN?

Do insiders and institutionals hold more shares of BBIO or NNNN?

Does the media prefer BBIO or NNNN?

Summary

How does Anbio Biotechnology compare to Axsome Therapeutics?

Which has more risk & volatility, AXSM or NNNN?

Do analysts recommend AXSM or NNNN?

Does the media prefer AXSM or NNNN?

Which has stronger earnings and valuation, AXSM or NNNN?

Do insiders and institutionals hold more shares of AXSM or NNNN?

Is AXSM or NNNN more profitable?

Summary

How does Anbio Biotechnology compare to Arrowhead Pharmaceuticals?

Which has more volatility & risk, NNNN or ARWR?

Do analysts rate NNNN or ARWR?

Does the media favor NNNN or ARWR?

Which has preferable earnings and valuation, NNNN or ARWR?

Do institutionals and insiders hold more shares of NNNN or ARWR?

Is NNNN or ARWR more profitable?

Summary

How does Anbio Biotechnology compare to Elanco Animal Health?

Which has more volatility & risk, NNNN or ELAN?

Do analysts rate NNNN or ELAN?

Does the media favor NNNN or ELAN?

Which has preferable earnings and valuation, NNNN or ELAN?

Do institutionals and insiders hold more shares of NNNN or ELAN?

Is NNNN or ELAN more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NNNN vs. The Competition

Anbio Biotechnology Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools